Literature DB >> 31649329

Initiation of Parkinson's disease from gut to brain by δ-secretase.

Eun Hee Ahn1, Seong Su Kang1, Xia Liu1, Guiqin Chen2, Zhentao Zhang2, Bindu Chandrasekharan1, Ashfaqul M Alam1, Andrew S Neish1, Xuebing Cao3, Keqiang Ye4.   

Abstract

Lewy pathology, composed of α-Synuclein (α-Syn) inclusions, a hallmark of Parkinson's disease (PD), progressively spreads from the enteric nervous system (ENS) to the central nervous system (CNS). However, it remains unclear how this process is regulated at a molecular level. Here we show that δ-secretase (asparagine endopeptidase, AEP) cleaves both α-Syn at N103 and Tau at N368, and mediates their fibrillization and retrograde propagation from the gut to the brain, triggering nigra dopaminergic neuronal loss associated with Lewy bodies and motor dysfunction. α-Syn N103 and Tau N368 robustly interact with each other and are highly elevated in PD patients' gut and brain. Chronic oral administration of the neurotoxin rotenone induces AEP activation and α-Syn N103/Tau N368 complex formation in the gut, eliciting constipation and dopaminergic neuronal death in an AEP-dependent manner. Preformed fibrils (PFFs) of α-Syn N103/Tau N368 are more neurotoxic and compact, and aggregate more quickly along the vagus nerve than their FL/FL counterparts or the individual fragments' fibrils. Colonic injection of PFFs induces PD pathologies, motor dysfunctions, and cognitive impairments. Thus, δ-secretase plays a crucial role in initiating PD pathology progression from the ENS to the CNS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31649329      PMCID: PMC6951265          DOI: 10.1038/s41422-019-0241-9

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  55 in total

1.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

2.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 3.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

4.  Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.

Authors:  K Arima; S Hirai; N Sunohara; K Aoto; Y Izumiyama; K Uéda; K Ikeda; M Kawai
Journal:  Brain Res       Date:  1999-10-02       Impact factor: 3.252

5.  Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.

Authors:  Takashi Ishizawa; Petri Mattila; Peter Davies; Dengshun Wang; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2003-04       Impact factor: 3.685

6.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

Review 7.  Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Authors:  C Warren Olanow; Patrik Brundin
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

8.  Phosphorylated alpha-synuclein in normal mouse brain.

Authors:  Yu Hirai; Shinobu C Fujita; Takeshi Iwatsubo; Masato Hasegawa
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

9.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

10.  Neurodegenerative changes initiated by presynaptic dysfunction.

Authors:  Toru Yasuda; Yasuto Nakata; Chi-Jing Choong; Hideki Mochizuki
Journal:  Transl Neurodegener       Date:  2013-08-07       Impact factor: 8.014

View more
  14 in total

Review 1.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

2.  Mitochondrial dysfunction triggers the pathogenesis of Parkinson's disease in neuronal C/EBPβ transgenic mice.

Authors:  Eun Hee Ahn; Kecheng Lei; Seong Su Kang; Zhi-Hao Wang; Xia Liu; Wei Hong; Yu Tian Wang; Laura E Edgington-Mitchell; Lingjing Jin; Keqiang Ye
Journal:  Mol Psychiatry       Date:  2021-09-06       Impact factor: 15.992

3.  Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer's disease mouse model.

Authors:  Chun Chen; Eun Hee Ahn; Seong Su Kang; Xia Liu; Ashfaqul Alam; Keqiang Ye
Journal:  Sci Adv       Date:  2020-07-29       Impact factor: 14.136

Review 4.  Brain regions susceptible to alpha-synuclein spreading.

Authors:  Yu-Jie Guo; Huan Xiong; Kang Chen; Jin-Jun Zou; Peng Lei
Journal:  Mol Psychiatry       Date:  2021-09-24       Impact factor: 15.992

Review 5.  Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.

Authors:  Namdoo Kim; Hyuck Jin Lee
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

6.  Targeted proteolytic products of τ and α-synuclein in neurodegeneration.

Authors:  Yuxing Xia; Grace M Lloyd; Benoit I Giasson
Journal:  Essays Biochem       Date:  2021-12-22       Impact factor: 8.000

7.  Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.

Authors:  Zachary A Sorrentino; Ethan Hass; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Jess-Karan S Dhillon; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2020-05-01       Impact factor: 3.046

8.  Gut inflammation triggers C/EBPβ/δ-secretase-dependent gut-to-brain propagation of Aβ and Tau fibrils in Alzheimer's disease.

Authors:  Chun Chen; Yunzhe Zhou; Hualong Wang; Ashfaqul Alam; Seong Su Kang; Eun Hee Ahn; Xia Liu; Jianping Jia; Keqiang Ye
Journal:  EMBO J       Date:  2021-07-14       Impact factor: 14.012

Review 9.  New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.

Authors:  Marina Lorente-Picón; Ariadna Laguna
Journal:  Biomolecules       Date:  2021-03-15

Review 10.  Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer's disease.

Authors:  Seong Su Kang; Eun Hee Ahn; Keqiang Ye
Journal:  Exp Mol Med       Date:  2020-08-28       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.